WilmerHale Represents Underwriters in $92M Public Offering of Candel Therapeutics

WilmerHale Represents Underwriters in $92M Public Offering of Candel Therapeutics

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.

WilmerHale represented the underwriters in the public offering by Candel Therapeutics, Inc. of 12,000,001 shares of common stock, reflecting the full exercise of the underwriters’ option to purchase 2,000,000 additional shares, and 3,333,333 pre-funded warrants to purchase shares of common stock. Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The offering priced on December 12, 2024 and closed on December 16, 2024.  Candel received approximately $92 million in gross proceeds, before deducting underwriting discounts and commissions and other offering expenses.  

The team consisted of Lisa Firenze, Scott Lunin, Leigh Krafchek, Erin Bruynell Gallagher and Whitley Horning, with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar Ph.D. on intellectual property matters.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel